Mr. Speaker, my question is for the Deputy Prime Minister. The intentions of the federal government remain unclear regarding former Bill C-91. In their attempt to have the supporting regulations changed, a group of government members are challenging openly and publicly the validity of the act designed to protect pharmaceutical companies manufacturing brand name drugs, companies that invest substantial amounts in the design and development of such drugs.
Does the Deputy Prime Minister agree with this open attack on Bill C-91 by several of her fellow government members, with the support of former Liberal minister Bob Kaplan, who now lobbies for generic drug manufacturers?